Get the Stockscreener App
49.57
1.54%
0.75
Mbx Biosciences Inc stock is traded at $49.57, with a volume of 106.76K.
It is up +1.54% in the last 24 hours and down -18.84% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$48.82
Open:
$49.15
24h Volume:
106.76K
Relative Volume:
0.18
Market Cap:
$2.39B
Revenue:
Net Income/Loss:
$-86.97M
P/E Ratio:
-20.49
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
-6.91%
1M Performance:
-18.84%
6M Performance:
+50.39%
1Y Performance:
+255.34%
1-Day Range:
$48.73
$51.30
1-Week Range:
$47.60
$54.03
52-Week Range:
$12.94
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
49.57 | 2.39B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-26 | Resumed | JP Morgan | Overweight |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX S-8及美國證券交易委員會申報文件 - Yahoo 財經
MBX Biosciences (NasdaqGS:MBX) Stock Forecast & Analyst Predictions - Simply Wall Street
MBX Biosciences (Nasdaq:MBX)Stock Analysis - simplywall.st
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - Yahoo Finance Singapore
MBX Biosciences to Participate in Upcoming Investor Conferences - marketscreener.com
MBX Biosciences will present in New York and online - Stock Titan
MBX Biosciences, Inc. Announces Appointment of Jeff Held as Chief Legal Officer - marketscreener.com
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - au.finance.yahoo.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - The Manila Times
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - Yahoo Finance
Lawyer who co-led a $2.4B acquisition joins MBX Biosciences - stocktitan.net
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - GlobeNewswire
MBX Biosciences Share Price Chart (MBX) - Investing.com UK
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Stability Report - vinanet.vn
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - sahmcapital.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com India
MBX Biosciences doses first patient in phase 3 HP trial By Investing.com - Investing.com Nigeria
MBX Biosciences (MBX) Slips 2.7% to $66.76, Holding Above Key Support at $63.42Sign of Weakness - dars.gov.et
MBX Biosciences Insiders Added US$1.06m Of Stock To Their Holdings - moomoo.com
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88 - moomoo.com
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - vinanet.vn
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayFibonacci Extension - siam.in
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - vinanet.vn
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Q2 2026 Earnings: Wider-than-Expected -$0.78 Loss Highlights Accelerated Pipeline InvestmentRevenue Estimate Trend - vinanet.vn
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceStop Run - dars.gov.et
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - stocktitan.net
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences Shares Lower After Q2 Loss Widens - Yahoo Finance
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mbx Biosciences Inc Stock (MBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Officer |
Aug 04 '26 |
Proposed Sale |
65.77 |
370 |
24,336 |
0 |
| Azoulay Salomon | Chief Medical Officer |
Aug 04 '26 |
Sale |
65.77 |
370 |
24,335 |
14,399 |
| Hawryluk P. Kent | Officer |
Aug 04 '26 |
Proposed Sale |
65.77 |
936 |
61,563 |
0 |
| Bartram Richard | Former Officer |
Jun 10 '26 |
Proposed Sale |
30.55 |
9,167 |
280,010 |
0 |
| Bartram Richard | Former Officer |
Jun 09 '26 |
Proposed Sale |
29.66 |
10,833 |
321,273 |
0 |
| Bartram Richard | Former Officer |
May 13 '26 |
Proposed Sale |
36.95 |
15,000 |
554,296 |
0 |
| Bartram Richard | Former Officer |
May 11 '26 |
Proposed Sale |
44.08 |
22,500 |
991,901 |
0 |
| Azoulay Salomon | Officer |
May 08 '26 |
Proposed Sale |
38.37 |
70,003 |
2,685,679 |
0 |
| Azoulay Salomon | Chief Medical Officer |
May 08 '26 |
Option Exercise |
11.65 |
70,003 |
815,348 |
69,769 |
| Bartram Richard | Former Officer |
May 08 '26 |
Proposed Sale |
37.96 |
10,000 |
379,562 |
0 |
3.92%
4.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):